Shexiang Baoxin Pill Corrects Metabolic Disorders in a Rat Model of Metabolic Syndrome by Targeting Mitochondria
Background: Metabolic syndrome (MS) is a global epidemic that has great socioeconomic and public health implications. This study reports observed effects of the Shexiang Baoxin Pill (SBP) in a rat model of MS and explores its underlying mechanisms of action.Methods: A diet-induced rat model of MS wa...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2018.00137/full |
| _version_ | 1811220483747610624 |
|---|---|
| author | Dan Wei Ningning Zheng Lanyan Zheng Leting Wang Liang Song Luning Sun |
| author_facet | Dan Wei Ningning Zheng Lanyan Zheng Leting Wang Liang Song Luning Sun |
| author_sort | Dan Wei |
| collection | DOAJ |
| description | Background: Metabolic syndrome (MS) is a global epidemic that has great socioeconomic and public health implications. This study reports observed effects of the Shexiang Baoxin Pill (SBP) in a rat model of MS and explores its underlying mechanisms of action.Methods: A diet-induced rat model of MS was established according to accepted methods, and the rats were randomly divided into two groups: a control group (0.9% NaCl, 100 mg/kg•d) and a SBP-treated group (SBP, 100 mg/kg•d). Systolic blood pressures, fasting blood glucose (FBS) levels, triglyceride (TG) levels, high-density lipoprotein cholesterol (HDL-C) levels, body weights, and abdominal perimeters were dynamically monitored and analyzed. Serum leptin, adiponectin, TNF-α, IL-6, and IL-10 levels were measured by ELISA. Leptin, adiponectin, TNF-α, IL-6, and IL-10 expression in adipose tissue, as well as AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-1α) expression in heart, liver, skeletal muscle, and adipose tissue was measured by western blot. Expression of the mitochondrial protein UCP2, Cytochrome b and ATPase was observed by immunofluorescent staining.Results: SBP significantly decreased serum TG, TC, LDL-C levels and increased HDL-C levels. SBP also optimized the leptin/adiponectin ratio by decreasing leptin expression and increasing adiponectin expression in adipose tissue. SBP antagonized inflammatory reactions by promoting IL-10 expression in adipose tissue while inhibiting TNF-α and IL-6 expression. SBP improved lipid metabolism by up-regulating the expression of AMPK and PGC-1α. Furthermore, SBP decreased the severity of MS and its complications by adjusting the expression of several mitochondrial proteins, including UCP2, Cytochrome b and ATPase.Conclusion: SBP exhibits prominent therapeutic effects in the setting of MS. Possible mechanisms of action may be related to its anti-inflammatory and anti-oxidative characteristics, as well as its effects on improving lipid metabolism and protecting mitochondrial function. |
| first_indexed | 2024-04-12T07:42:35Z |
| format | Article |
| id | doaj.art-c360ac71a4024497b7fea4bd98254425 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T07:42:35Z |
| publishDate | 2018-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-c360ac71a4024497b7fea4bd982544252022-12-22T03:41:47ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122018-03-01910.3389/fphar.2018.00137333281Shexiang Baoxin Pill Corrects Metabolic Disorders in a Rat Model of Metabolic Syndrome by Targeting MitochondriaDan Wei0Ningning Zheng1Lanyan Zheng2Leting Wang3Liang Song4Luning Sun5Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, ChinaDepartment of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, ChinaDepartment of Pathogen Biology, College of Basic Medical Science, China Medical University, Shenyang, ChinaShanghai Hutchison Pharmaceuticals, Shanghai, ChinaWanleibio Co., Ltd., Shenyang, ChinaDepartment of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, ChinaBackground: Metabolic syndrome (MS) is a global epidemic that has great socioeconomic and public health implications. This study reports observed effects of the Shexiang Baoxin Pill (SBP) in a rat model of MS and explores its underlying mechanisms of action.Methods: A diet-induced rat model of MS was established according to accepted methods, and the rats were randomly divided into two groups: a control group (0.9% NaCl, 100 mg/kg•d) and a SBP-treated group (SBP, 100 mg/kg•d). Systolic blood pressures, fasting blood glucose (FBS) levels, triglyceride (TG) levels, high-density lipoprotein cholesterol (HDL-C) levels, body weights, and abdominal perimeters were dynamically monitored and analyzed. Serum leptin, adiponectin, TNF-α, IL-6, and IL-10 levels were measured by ELISA. Leptin, adiponectin, TNF-α, IL-6, and IL-10 expression in adipose tissue, as well as AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-1α) expression in heart, liver, skeletal muscle, and adipose tissue was measured by western blot. Expression of the mitochondrial protein UCP2, Cytochrome b and ATPase was observed by immunofluorescent staining.Results: SBP significantly decreased serum TG, TC, LDL-C levels and increased HDL-C levels. SBP also optimized the leptin/adiponectin ratio by decreasing leptin expression and increasing adiponectin expression in adipose tissue. SBP antagonized inflammatory reactions by promoting IL-10 expression in adipose tissue while inhibiting TNF-α and IL-6 expression. SBP improved lipid metabolism by up-regulating the expression of AMPK and PGC-1α. Furthermore, SBP decreased the severity of MS and its complications by adjusting the expression of several mitochondrial proteins, including UCP2, Cytochrome b and ATPase.Conclusion: SBP exhibits prominent therapeutic effects in the setting of MS. Possible mechanisms of action may be related to its anti-inflammatory and anti-oxidative characteristics, as well as its effects on improving lipid metabolism and protecting mitochondrial function.http://journal.frontiersin.org/article/10.3389/fphar.2018.00137/fullmetabolic syndromeShexiang Baoxin Pilllipid metabolisminflammationmitochondrial proteinsreactive oxygen species |
| spellingShingle | Dan Wei Ningning Zheng Lanyan Zheng Leting Wang Liang Song Luning Sun Shexiang Baoxin Pill Corrects Metabolic Disorders in a Rat Model of Metabolic Syndrome by Targeting Mitochondria Frontiers in Pharmacology metabolic syndrome Shexiang Baoxin Pill lipid metabolism inflammation mitochondrial proteins reactive oxygen species |
| title | Shexiang Baoxin Pill Corrects Metabolic Disorders in a Rat Model of Metabolic Syndrome by Targeting Mitochondria |
| title_full | Shexiang Baoxin Pill Corrects Metabolic Disorders in a Rat Model of Metabolic Syndrome by Targeting Mitochondria |
| title_fullStr | Shexiang Baoxin Pill Corrects Metabolic Disorders in a Rat Model of Metabolic Syndrome by Targeting Mitochondria |
| title_full_unstemmed | Shexiang Baoxin Pill Corrects Metabolic Disorders in a Rat Model of Metabolic Syndrome by Targeting Mitochondria |
| title_short | Shexiang Baoxin Pill Corrects Metabolic Disorders in a Rat Model of Metabolic Syndrome by Targeting Mitochondria |
| title_sort | shexiang baoxin pill corrects metabolic disorders in a rat model of metabolic syndrome by targeting mitochondria |
| topic | metabolic syndrome Shexiang Baoxin Pill lipid metabolism inflammation mitochondrial proteins reactive oxygen species |
| url | http://journal.frontiersin.org/article/10.3389/fphar.2018.00137/full |
| work_keys_str_mv | AT danwei shexiangbaoxinpillcorrectsmetabolicdisordersinaratmodelofmetabolicsyndromebytargetingmitochondria AT ningningzheng shexiangbaoxinpillcorrectsmetabolicdisordersinaratmodelofmetabolicsyndromebytargetingmitochondria AT lanyanzheng shexiangbaoxinpillcorrectsmetabolicdisordersinaratmodelofmetabolicsyndromebytargetingmitochondria AT letingwang shexiangbaoxinpillcorrectsmetabolicdisordersinaratmodelofmetabolicsyndromebytargetingmitochondria AT liangsong shexiangbaoxinpillcorrectsmetabolicdisordersinaratmodelofmetabolicsyndromebytargetingmitochondria AT luningsun shexiangbaoxinpillcorrectsmetabolicdisordersinaratmodelofmetabolicsyndromebytargetingmitochondria |